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doi:10.1016/j.ejvs.2010.12.026Abstract Objectives: To compare aortoenteric fistula (AEF) outcome after endovascular (EV-
AEFR) or open repair (O-AEFR).
Design: Multicentre retrospective comparative study.
Materials/Methods: 25 patients with AEF (24 secondary, 23 males, median age 75 years) after
aortic surgery (median four years). Preoperative sepsis was evident in 19 cases. Eight patients
were managed with EV-AEFR and 17 with O-AEFR.
Results: The two groups were comparable in preoperative characteristics. In-hospital
mortality after EV-AEFR was lower compared to O-AEFR (0% and 35%, respectively,
p Z 0.13). Similarly, morbidity after EV-AEFR was lower compared to O-AEFR (25% and 77%,
respectively, p Z 0.028). There was a trend for worse recurrence-free, sepsis-free, re-opera-
tion-free and AEF-related death-free rates after EV-AEFR, while the early survival advantage of
EV-AEFR was lost after two years and the overall long-term survival rates (perioperative
mortality included) of the two groups were similar. Preoperative sepsis had no effect on recur-
rence and sepsis-free rates (p Z 0.94 and p Z 0.92, respectively), but it was associated with
worse two year overall survival (24% vs 50%, pZ 0.32). On multivariate analysis, the number of
symptoms (two vs one) at presentation was the single predictor of worse re-operation rates,
AEF-related and overall survival.education questions on this paper, please go to www.vasculareducation.com and click on ‘CME’
of Vascular Surgery, University Hospital of Patras, 26 504 Rio, Patras, Greece. Tel.: þ30 2613 603406;
(S.K. Kakkos).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
626 S.K. Kakkos et al.Conclusions: EV-AEFR was associated with no postoperative mortality in this study and can
achieve satisfactory short and long-term results, comparable to O-AEFR. Further trials should
focus on the role of EV-AEFR in patients at high risk for O-AEFR, due to shock or co-morbidities,
or as a bridging procedure.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Despite prompt open surgery, aortoenteric fistula (AEF),
mostly secondary after abdominal aortic aneurysm (AAA)
repair, remains a highly lethal condition, with mortality
rates of approximately 50%.1 Although these rates seem to
have decreased over time,1 the prognosis is still dismal,
especially in the presence of co-morbidities, risk factors
such as advanced age or severe complications, such as
haemorrhagic shock and sepsis. These observations call for
a less invasive treatment modality. During the past decade,
endovascular AEF repair (EV-AEFR) has emerged as a less
morbid approach,27 despite the fact that its exact role as
a definite or bridge treatment has to be defined, the latter
being suggested because of a high incidence of recurrent
bleeding and sepsis.8 Meta-analyses of case series of either
method might be less valid than a direct comparison; so far,
there is only one such study comparing EV-AEFR with open
AEF repair (O-AEFR), but because it is small, any conclu-
sions drawn from it need to be validated.6
The aim of our study was to compare short and long-
term outcome after EV-AEFR or O-AEFR, to help the deci-
sion-making process of patient care.
Material and Methods
During a 12-year period (1998e2009), 25 patients with AEF
(24 secondary, 23 males, median age 75 years) were oper-
ated on in six Greek Vascular Surgery Departments. Data
were retrospectively collected in this multicentre
comparative study; patients were divided in two groups,
EV-AEFR and O-AEFR. Local expertise, surgeon preference
and availability of the appropriate endograft influenced the
decision-making process. Eight patients were managed with
EV-AEFR and 17 with O-AEFR. Details of some patients in
the EV-AEFR group have been partially provided in pub-
lished case reports.7,9,10 AEFs occurred after a median of 4
years after aortic surgery (endovascular aneurysm repair
(EVAR) in four cases), while preoperative sepsis was evident
in 19 cases (76%, with fever in 14, (56%)).
Statistics
All data were analysed with Statistical Package for Social
Sciences (SPSS) 17 or PASW statistics 18 (SPSS Inc., Chicago,
IL, USA). Because of the small sample size, non-parametric
tests were used. Categorical data were analysed with chi-
square or Fisher’s exact test, where appropriate. Event
rates during follow-up included recurrence, sepsis,
combined recurrence and sepsis, re-operation, AEF-related
death and overall survival; these were evaluated and
graphically depicted with the KaplaneMeier curve meth-
odology, while the log-rank test was used to compare the
event rates among the various subgroups. To increase the
power of the study, postoperative events were included,
with the exception of tests studying the effect ofantibiotics prescribed at discharge. Cox proportional-
hazard models were used for multivariate analysis.
Results
Patient demographics in relation to study group are shown in
Table 1. The two study groups were comparable in terms of
preoperative characteristics. Patient symptoms and preop-
erative investigations are shown in Table 2. There was a trend
for preoperative sepsis being less common in the EV-AEFR
group compared with the O-AEFR group. Further, computed
tomography (CT) findings of periprosthetic inflammation, air
or pseudo-aneurysm formation in the EV-AEFR group (100%,
38% and 38%, respectively) and the O-AEFR group (81%, 94%
and 6%, respectively) were not significantly different
(pZ 1.00, pZ 0.07 and pZ 0.09, respectively). One patient
in the O-AEFR group had a periprosthetic abscess formation.
Periprosthetic air was observed more often in patients with
preoperative fever (86%), raised inflammatory markers (92%)
and sepsis (83%) compared with those without these clinical
presentations (40%, p Z 0.032, 36%, p Z 0.008, 17%,
pZ 0.007, respectively).
Participating institutions managed between 1 and 8
cases. Five institutions performed at least one EV-AEFR,
and all institutions performed O-AEFR. EV-AEFR was per-
formed in 36% (4/11) of all cases performed through 2007
inclusive and in 29% in more recent cases (p Z 1.00,
Fisher’s exact test). Operative findings and procedures
performed in the EV-AEFR and O-AEFR groups are shown in
Table 3. AEF variety and location (duodenum in 80%) were
similar between the two study groups. A variety of endo-
vascular procedures were performed, with placement of
aortic cuff extenders being more common, followed by
aortouniiliac endografting and femoroefemoral bypass. In
the O-AEFR group, graft removal, closure of the aortic
stump and intestine and axillobifemoral bypass grafting
(delayed in one patient) were performed in 12 (71%)
patients. In the remaining five patients (two of them with
a paraprosthetic AEF/graft-enteric erosion), the graft was
not removed; this was due to the fact that in one of them
the AEF was primary (as a result of a psoas abscess and the
aortic defect was sutured), in three of them it was an
endograft for AAA repair and in the last the AEF was caused
by a proximal anastomotic pseudo-aneurysm, which was
repaired with in situ graft placement. Simple intestinal
repair was performed in half of O-AEFRs, with complex
repair (resection or duodenal closure and restoration of the
intestinal continuity) being performed in the remainder. All
patients received broad-spectrum antibiotics started
preoperatively and continued throughout patient
discharge. Median (interquartile) number of antibiotics in
the EV-AEFR and O-AEFR groups was 2 (2e3) and 2 (2e3),
respectively (pZ 0.54) (information not available for three
patients, two of them in the O-AEFR group).
Table 1 Patient baseline characteristics and pertinent history in the two study groups. Numerical data are expressed as
median (interquartile range).
Characteristic Group p value All patients (n Z 25)
EV-AEFR (n Z 8) O-AEFR (n Z 17)
Age (years) 75.5 (71e78) 73.5 (59e80) 0.66 75 (60.5e79.5)
Gender (M/F) 8/0 15/2 1.00 23/2
AEF type (secondary/primary) 8/0 16/1 1.00 24/1
Indication for primary operation
AAA 5 (63%) 10 (63%) 1.00 15 (63%)
AIOD 3 (37%) 6 (37%) 16 (37%)
Type of primary operation
Open repair or bypass grafting 8 (100%) 12 (75%) 0.26 20 (83%)
Endovascular repair 0 (0%) 4 (25%) 4 (17%)
Time since original aortic surgery (years) 4 (1e7.5) 3.5 (1e8.8) 0.85 4 (1.1e7.5)
AAA: abdominal aortic aneurysm, AIOD: aortoiliac occlusive disease.
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Postoperative complications are shown in Table 4.
Morbidity after EV-AEFR was lower compared with O-AEFR
(25% and 77%, respectively, p Z 0.028, odds ratio 98, 95%
confidence interval (C.I.) 1.4e69). Morbidity was higher in
patients with periprosthetic air (86%) compared with those
without air (25%, pZ 0.032, odds ratio 9, 95% C.I. 1.3e64).
Similarly, morbidity was higher in patients with perioper-
ative sepsis or raised inflammatory markers (74% and 86%,
respectively) compared with those without these charac-
teristics (17%, p Z 0.023, odds ratio 14, C.I. 1.3e151 and
27%, p Z 0.005, odds ratio 16, C.I. 2.2e118, respectively).
No other associations were identified. In-hospital mortality
after EV-AEFR and O-AEFR was 0% and 35%, respectively
(pZ 0.13). Causes of death included multiple organ failure
(nZ 4), sepsis (nZ 1) and intra-operative arrest and deathTable 2 Patient symptoms and preoperative investigations in t
Characteristic Group
EV-AEFR (n Z 8) O
Presenting symptom
Isolated GI bleeding 4 (50%)a
Isolated fever 0 (0%)
Combination of both 4 (50%)
Active hemorrhage 3 (38%)
Preoperative infection (n, %) 4 (50%) 1
Fever 4 (50%) 1
Raised inflammatory markersb 2 (25%) 1
Preoperative investigations
CTA 8 (100%) 1
Oesophagogastroduodenoscopy 7 (88%) 1
a One case with coexisting limb ischaemia.
b White cell count (>11,000/mm3), ESR (>20 mm/h) or CRP (>1 mg(n Z 1). Postoperative hospitalisation (median and inter-
quartile range) in the EV-AEFR and O-AEFR groups was 10
(8e29) days and 21 (8e36) days, respectively (p Z 0.48).
Intensive care unit (ICU) stay (median and interquartile
range) in the EV-AEFR and O-AEFR groups was 1 (0e3) days
and 2 (0.5e8) days, respectively (p Z 0.19). Patients, who
had O-AEFR and their graft was not removed during this
index operation (n Z 4), had higher mortality (75%)
compared with the remaining patients of both groups (14%,
p Z 0.03, odds ratio 18, 95% C.I. 1.4e236). Mortality in
patients with preoperative sepsis was 32%, compared with
0% in those without sepsis (pZ 0.28). Further, mortality in
patients of the O-AEFR group, who had duodenal closure
and gastric diversion, was 20%, compared with 33% in those
who had simple primary repair and 67% in whom resection
with primary anastomosis was performed (p Z 0.40).
Postoperative mortality was not associated with any otherhe endovascular and open groups.
p value All patients (n Z 25)
-AEFR (n Z 17)
0.49
7(41%) 11 (44%)
3 (18%)a 3 (12%)
7 (42%) 11 (44%)
5 (29%) 1.00 8 (32%)
5 (88%) 0.06 19 (76%)
0 (59%) 1.00 14 (56%)
2 (71%) 0.08 14 (56%)
6 (94%) 1.00 24 (96%)
0 (59%) 0.21 17 (68%)
/dL).
Table 3 Operative findings and procedures performed in the endovascular and open groups. Intestinal involvement in the
EV-AEFR group was mostly determined by preoperative investigations.
Characteristic Group p value All patients (n Z 25)
EV-AEFR (n Z 8) O-AEFR (n Z 17)
Intestine segment involved
Duodenum 6 (75%) 14 (82%) 1.00 20 (80%)
Jejunum or ileus 2 (25%) 3 (18%) 5 (20%)
AEF variety
Direct aortoenteric communication (anastomotic) 8 (100%) 14 (82%) 0.53 22 (88%)
Paraprosthetic (graft-enteric erosion) 0 (0%) 3 (18%) 3 (12%)
Endovascular procedures
Aortouniiliac endograft þ femorofemoral bypass grafting 3 (38%) 3 (12%)
Aortic cuff extenders 4 (50%) 4 (16%)
Modular endograft 1 (12%) 1 (4%)
Open procedures
Graft removal þ axillobifemoral bypass grafting 12 (71%)a 12 (48%)a
Graft left in place 4 (23%) 4 (23%)
Primary closure 1 (6%) 1 (6%)
Intestinal repair
Simple primary repair 1 (13%) 9 (53%)b 9 (36%)b
Resection with primary anastomosis 3 (18%)c 3 (12%)c
Duodenal closure þ gastric diversiond 5 (29%) 6 (24%)
a Delayed axillofemoral bypass grafting in one patient.
b Hybrid repair in one patient.
c Aortic omentoplasty in one patient.
d Gastrojejunostomy (n Z 3) or Roux-en-Y reconstruction (n Z 2).
628 S.K. Kakkos et al.preoperative clinical characteristic or procedures per-
formed. Median (interquartile) number of antibiotics taken
after hospital discharge in the EV-AEFR and O-AEFR groups
was 1 (1e2) and 1(0e1), respectively (p Z 0.034) (infor-
mation not available in three patients, two of them in the
EV-AEFR group). Percentage of patients in the EV-AEFR and
O-AEFR groups receiving antibiotics for more than 6 months
was 67% and 20%, respectively (p Z 0.12).Table 4 Complications and mortality in the endovascular and o
Complication Group
EV-AEFR (n Z 8) O-AEFR (n Z 1
Multiple organ failure 0 (0%) 5 (29%)a
Bleeding 0 (0%) 2 (12%)b
Ischemic leg complications 1 (13%) 5 (29%)
Limb loss 1 (13%) 2 (12%)
Other complications 1 (13%)c 4 (24%)d
Morbidity (total) 2 (25%)e 13 (77%)
Mortality 0 (0%) 6 (35%)
a Gastrointestinal anastomosis leak in one patient.
b Recurrent bleeding in two patients (stump blowout in one of them
ligation, initially, followed by recurrence and suprarenal ligation and
c Respiratory failure and sepsis.
d MI, wound infection, gastrointestinal fistula, intra-operative arres
e Three additional patients with preoperative sepsis had postoperati
per se), managed successfully with antibiotics alone.Long-term outcome
Regarding the main outcome measures of the study:
recurrence-free, sepsis-free, combined event-free, re-
operation-free, AEF-related death-free and overall long-
term survival rates (perioperative mortality included),
there was a trend for worse long-term results of the EV-
AEFR patients, although the difference did not reachpen groups.
p value Odds ratio (95% c.i.) All patients (n Z 25)
7)
0.140 N/A 5 (20%)
1.00 N/A 2 (12%)
0.624 2.9 (0.28e30.3) 6 (24%)
1.00 0.93 (0.07e12.1) 3 (12%)
1.00 2.1 (0.2e23.1) 5 (20%)
0.028 9.8 (1.4e69) 15 (60%)
0.129 N/A 6 (24%)
), managed with simple suture and repeat infrarenal aortic stump
splenorenal bypass, respectively.
t.
vely persistent sepsis (therefore not considered as a complication
Table 5 Two-year event-free and survival rates in the two
study groups.
Two-year event rate EV-AEFR O-AEFR p value
Recurrence-free rate 51% 78% 0.58
Sepsis-free rate 28% 70% 0.22
Reoperation-free rate 30% 64% 0.58
AEF-related death-free rate 17% 38% 0.59
Overall survival rate 15% 38% 0.92
Figure 2 Sepsis-free rates of the EV-AEFR and O-AEFR study
groups. A non significant trend for higher sepsis-free rates in O-
AEFR compared to EV-AEFR was evident. Sepsis was defined as
recurrent or new onset sepsis.
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survival advantage of EV-AEFR was lost by the second year
of follow-up (Fig. 5).
Recurrent AEF was developed in four patients. Two of
them, where recurrence occurred after EV-AEFR and repeat
EV-AEFR was performed (unsuccessfully in one of them),
were eventually managed (due to repeat bleeding and
sepsis, respectively) with conversion to conventional
O-AEFR (graft removal and axillobifemoral bypass grafting).
The two remaining patients, who originally had EV-AEFR
and O-AEFR, respectively, were managed with graft
removal/axillobifemoral bypass grafting and repeat aortic
stump ligation; thus, 75% of all recurrent AEFs were in
patients who had undergone EV-AEFR and this accounted
for 3/8 (38%) of the total number of EV-AEFRs performed.
Recurrent or new-onset sepsis developed in six patients,
in four of them after EV-AEFR. Management included
conservative measures (antibiotics) in five patients (three
of them succumbed, and two had subsequent graft
removal/axillobifemoral bypass grafting) and graft
removal/axillobifemoral bypass grafting in the last one.
Two above-knee amputations, one in each study group,
were performed during long-term follow-up, and an addi-
tional patient of the O-AEFR developed graft thrombosis. In
summary, four patients (50%) of the EV-AEFR group (threeFigure 1 AEF recurrence-free rates of the EV-AEFR and O-
AEFR study groups were equivalent.
Figure 3 Freedom from the combined endpoint of AEF
recurrence or development of sepsis (either new or recurrent)
in the EV-AEFR and O-AEFR study groups was equivalent;
a delay in the former group was noted.
Figure 4 Re-operation-free rates of the EV-AEFR and O-AEFR
study groups were equivalent, but the corresponding curves
diverged around the 18th postoperative month, with higher
rates being observed in the latter group.
Figure 6 Overall death-free rates of the EV-AEFR and O-AEFR
study groups were equivalent, but a delay in the former group
was noted. The survival curves crossed toward the end of the
second postoperative year.
630 S.K. Kakkos et al.due to sepsis, one due to recurrent AEF after a mean of 16.5
months, median 17.5 months) crossed over to the O-AEFR
group with 100% mortality. An additional patient of the EV-
AEFR group died after 2 years as a result of sepsis that wasFigure 5 AEF-related death-free rates of the EV-AEFR and O-
AEFR study groups were equivalent, but a delay in the former
group was noted. The survival curves crossed at two years.managed conservatively, with two more dying because of
a myocardial infarction at 6 months and 5 years, respec-
tively. Of the 11 patients of the O-AEFR group, who were
discharged alive, two patients died as a result of recurrent
bleeding at 3 and 6 months, respectively, one patient after
10 months as a result of sepsis that was managed conser-
vatively, two patients after an above-knee amputation
(with co-current AEF-related sepsis) and cardiac surgery, at
11 and 84 months, respectively and one patient as a result
of an myocardial infarction at 33 months. A flowchart
summarising procedures and outcomes in relation to the
study group is shown in Fig. 7.
Factors affecting long-term outcome
Factors affecting recurrence rates
Preoperative sepsis had no effect on recurrence-free rates
(p Z 0.94) and so the remaining clinical characteristics on
univariate or multivariate analysis.
Factors affecting new onset or recurrence of sepsis
There was a lower sepsis-free rate at 2 years in patients
receiving two antibiotics after discharge (0%) compared
with those who received only one antibiotic (63%) or no
antibiotics (100%, p for trend Z 0.006). There was a lower
sepsis-free rate at 2 years in patients receiving antibiotics
for longer than 6 months (22%) compared with those who
received antibiotics for 6 months or less (83%, p Z 0.02).
Preoperative sepsis had no effect on sepsis-free rates
(p Z 0.92) and so the remaining clinical characteristics on
univariate or multivariate analysis.
25 patients with AEF
EV-AEFR: n=8
Morbitity: n=13 (77%)*
O-AEFR: n=17
Morbitity: n=2 (25%)
Mortality:    n=6   (35%)Mortality:    n=0 (0%)
Discharged alive: n=8 Discharged alive: n=11
AEF recurrence: n=2
Redo EV-AEFR: n=2
AEF recurrence: n=2
Re-operation: n=2
O-AEFR: n=4
failure (n=1) sepsis (n=1)
Sepsis: n=3, cons Mx
(n=1) (AEF recurrence, n=1)
Sepsis: n=2, cons Mx
MI: n=2
(n=1)
Death: n=7
(n=4)
MI: n=1 CSx: n=1 Death: n=6
Total alive: n=1 Total alive: n=5
,
*recurrent bleeding (n=1), cons Mx: conservative management, CSx: cardiac surgery
Figure 7 Flow chart summarizing procedures and outcomes in relation to study group.
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recurrence or new-onset/recurrence of sepsis
There was a lower combined event-free rate at 2 years in
patients whose original repair was AAA repair (18%)
compared with those who had aortobifemoral bypass
grafting (89%, p Z 0.02).
There was a lower combined event-free rate at 2 years in
patients,whohadcomplexbowel repair (bowel resectionwith
primary anastomosis or duodenal closure) (26%), compared
with simple primary repair (83%, pZ 0.018). No other asso-
ciations were found on univariate or multivariate analysis.
Factors affecting re-operation rates
There was a lower re-operation-free rate at 10 months in
patients, who had duodenal closure (17%), compared with
simple primary repair (87%, p Z 0.012). No other associa-
tions were found. On multivariate analysis, the number of
symptoms (two vs. one) at presentation was the single
predictor of re-operation (p Z 0.04, relative risk 5.8, 95%
C.I. 1.1e31).
Factors affecting AEF-related death
There was a worse AEF-related survival at 2 years in
patients whose original repair was AAA repair (8%)
compared with those who had aortobifemoral bypassgrafting (78%, p Z 0.013). Patients, who had O-AEFR and
their graft was not removed during this index operation
(n Z 4), had worse AEF-related 2-year survival compared
with the remaining patients of both groups (0% vs. 39%,
p < 0.001). No other associations were found. On multi-
variate analysis, the number of symptoms (two vs. one) at
presentation was the single predictor of worse survival
(p Z 0.018, relative risk 13.8, 95% C.I. 1.6e123).
Factors affecting overall survival
There was a worse survival at 2 years in patients who pre-
sented with fever (11%) compared with those without fever
(52%, p Z 0.04). Two-year overall survival in patients with
preoperative sepsis was worse (24%) compared with those
without such presentation (50%, pZ 0.32, Fig. 8). There was
a worse survival at 2 years in patients whose original repair
was AAA repair (8%), compared with those who had aortobi-
femoral bypass grafting (50%, pZ 0.035). Patients, who had
O-AEFR and their graft was not removed during this index
operation (n Z 4), had worse overall 2-year survival
compared with the remaining patients of both groups (0% vs.
37%, p Z 0.001). There was a worse survival at 2 years in
patients receiving antibiotics for longer than 6 months (0%)
compared with those who received antibiotics for 6 months
or less (67%, pZ 0.03). No other associations were found. On
Figure 8 Preoperative sepsis was associated with worse two-
year overall survival (24% vs 50%) but the difference did not
reach statistical significance (p Z 0.32).
632 S.K. Kakkos et al.multivariate analysis, the number of symptoms (two vs. one)
at presentation was the single predictor of worse survival
(pZ 0.012, relative risk 17.8, 95% C.I. 1.8e135).
Discussion
In the present investigation, we reported on a multicentre
study comparing EV-AEFR with O-AEFR. Despite not being
a randomised study, the two study groups were comparable,
although therewas a strong trend for patients in the EV-AEFR
group to have less often signs of infection preoperatively,
indicating that bleeding dominated the clinical picture. AEF
variety and the intestine segment involved were comparable
with what previously reported,1 although preoperative
infection occurred more often in our study.
The main advantages of EV-AEFR are the low morbidity,
mortality and associated hospitalisation, considerably less
than O-AEFR. EV-AEFR is a less invasive method, does not
require cross-clamping and thus is associated with less
reperfusion injury and therefore is better tolerated inTable 6 Lessons learnt from the current study.
 EV-AEFR has lower morbidity, compared to O-AEFR.
 EV-AEFR has no mortality, compared to O-AEFR,
where only 2/3 of patients were discharged alive.
 Recurrence-free and sepsis-free rates of the
two treatment methods were similar.
 Due to sepsis and/or recurrent AEF, the early survival
advantage of EV-AEFR was lost after two years and
overall long-term survival rates were similar.
 Bleeding and fever on presentation are poor
prognostic features.
 Future trials should focus on the role of EV-AEFR, a)
in patients at high risk for O-AEFR (due to shock
or co-morbidities) or b) as a bridging procedure.patients, who are often debilitated and elderly, with
bleeding and sepsis. Although minimally invasive, EV-AEFR
has been reported to have some morbidity and mortality,6,8
most likely the result of haemodynamic instability and
infection in a group of mostly elderly patients. However,
these figures compare favourably with the outcome of O-
AEFR, both in our series and the literature.1,6 Of note,
mortality (35%) and morbidity (77%) after O-AEFR in our
study were similar to what reported by others.1,11 Multiple
organ failure was a particularly frequent complication after
O-AEFR, with limb ischaemia, observed also by others,12
being equally frequent. Mortality was worse in patients,
who did not have graft removal, compared with the
remainder, as expected; perioperative mortality with this
type of management has been reported to be higher
compared with more radical procedures,1 a fact that
favours the radical procedures in fit patients. In addition,
certain trends were observed for preoperative sepsis and
simple bowel repair which were associated with worse
short-term outcomes, consistent with previous studies.11,13
As simple bowel repair has been associated with fatal
leak,11 we favour an aggressive management of the intes-
tinal defect and suggest further study of complex
duodenum closure, observed to be associated by others
with worse outcome.13 Compared with elective EVAR,
hospitalisation after O-AEFR in our series is significantly
longer; this might partially reflect the need for intravenous
antibiotics, especially to treat patients with persistent
sepsis. Nevertheless, in our series, O-AEFR was associated
with longer hospitalisation compared with EV-AEFR; similar
results have been previously reported.6
Long-term complications after EV-AEFR and O-AEFR were
equally encountered in our study; although O-AEFR is
supposed to be a “permanent” solution, it is however
plagued by a high rate of recurrent bleeding (aortic stump
related) and septic complications. In the short term, recur-
rent bleeding and re-operation free rates are in favour of EV-
AEFR, while, in the long term, bleeding and sepsis-free rates
are better after O-AEFR (Figs. 1 and 2); our finding of a high
incidence of recurrent or newonset of sepsis after EV-AEFR is
consistent with previous reports.4,8,14 Similarly, recurrent
bleeding after EV-AEFR has been reported to occur very
often.15 However, the small number of patients (especially in
the EV-AEFR) did not permit statistical significance, repre-
senting most likely a type II statistical error. More impor-
tantly, disease-related and overall survivalwere consistently
better for the EV-AEFR group, a difference that persisted up
to 24 months postoperatively, until the late mortality rate
associated with graft removal offset the early survival
benefit due to the absence of postoperative mortality. It
should be noted that patients with AEFs have limited overall
survival,6 and 2-year survival rates after O-AEFR average
30%,16 figuring similar to our results.
In our study, patients whose original repair was AAA repair
developed recurrence and/or sepsis during follow-up more
often, compared with those who had had aortobifemoral
bypass grafting as also worse survival rates. The reason for
this complicated course is unclear and could be related to the
presence of the aneurysm sac, left in place after AAA repair,
which could make infection eradication more difficult; the
latter is likely associated with worse outcome in infected
aneurysms.17,18 Similarly, prognosis was worse for patients,
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primary repair, a result most likely of worse local sepsis.
Simple primary repair was also associated with fewer re-
operations. Sepsis-free rateswereworse inpatients receiving
one or two antibiotics after discharge, especially if these
were taken for longer than 6 months. We believe that this
finding might be related to the fact that antibiotics are
routinely prescribed for a prolonged period in patients after
EV-AEFR, compared with selective use after O-AEFR,19 and to
the fact that the formerdevelop recurrent or newsepsismore
often. Of note, survival was worse in patients who presented
with fever. Finally, on multivariate analysis, complex
presentation (mostly bleeding with fever) was associated
with a worse survival outcome compared with patients pre-
senting with a single symptom. Sepsis is known to be associ-
atedwithworsepatient survival after EV-AEFR,20 andperhaps
the combinationwith bleeding aggravates its prognostic role.
AEF-relatedandoverall survival in thosepatients,whodidnot
have graft removal, was significantly worse compared with
the remainder, findings related to the worse perioperative
mortality associated with this type of management.1
The long-term complications after EV-AEFR indicate
that this method should preferentially serve as a bridge to
open repair (O-AEFR) while patients are haemodynami-
cally stabilised, local and systemic sepsis is managed and
co-morbidities are worked up. This process of improving
patient fitness and excluding those who are not good
candidates could theoretically improve the results of O-
AEFR, in both the short- and long-term, the latter being
historically dismal.16 Alternatively, fit patients who had
EV-AEFR could be followed-up closely until complications
arise and have O-AEFR on an urgent or semi-elective basis.
Study limitations include its non-randomised design and
the relatively small number of patients, especially in the
EV-AEFR group. Longer follow-up in a larger set of
patients could yield additional observations and identify
subgroups in which EV-AEFR is not associated with long-
term complications, such as sepsis or AEF recurrence.
Future work should be directed towards clarifying these
questions. Having said that, the rarity, fortunately, of
AEF, in the era of declining open aortic procedures, makes
very difficult the design of a randomised study comparing
EV-AEFR with O-AEFR. In situ O-AEFR with homografts,
shown to achieve promising short- and long-term results,
superior to conventional methods in one study,21 but
inferior in another,22 deserves further research. A
summary of the lessons learnt from the current study is
shown in Table 6.
In conclusion, EV-AEFR was shown to have fewer
complications and lower mortality, but this short-term
advantage was lost during the second postprocedural year,
which indicates that EV-AEFR should serve as a bridging
option in selected patients. Further trials should focus on
the role of EV-AEFR in patients at high risk for O-AEFR, due
to shock or co-morbidities, or as a bridge therapy, and
investigate methods to eliminate sepsis in an effort to
improve patient survival.
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